On Friday, LENZ Therapeutics Inc (NASDAQ: LENZ) opened lower -25.96% from the last session, before settling in for the closing price of $24.5. Price fluctuations for LENZ have ranged from $16.53 to $50.40 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -181.63% annually for the last half of the decade. Company’s average yearly earnings per share was noted -10.97% at the time writing. With a float of $28.17 million, this company’s outstanding shares have now reached $28.59 million.
LENZ Therapeutics Inc (LENZ) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of LENZ Therapeutics Inc is 10.95%, while institutional ownership is 91.17%. The most recent insider transaction that took place on Nov 17 ’25, was worth 261,022. In this transaction Chief Commercial Officer of this company sold 10,000 shares at a rate of $26.10, taking the stock ownership to the 4,733 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 40,000 for $25.60, making the entire transaction worth $1,024,000.
LENZ Therapeutics Inc (LENZ) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.46 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.4) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.93% during the next five years compared to -181.63% drop over the previous five years of trading.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
Check out the current performance indicators for LENZ Therapeutics Inc (LENZ). In the past quarter, the stock posted a quick ratio of 12.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -2.82 in one year’s time.
Technical Analysis of LENZ Therapeutics Inc (LENZ)
Let’s dig in a bit further. During the last 5-days, its volume was 2.01 million. That was better than the volume of 0.52 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.08%.
During the past 100 days, LENZ Therapeutics Inc’s (LENZ) raw stochastic average was set at 7.03%, which indicates a significant decrease from 14.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.42 in the past 14 days, which was lower than the 2.45 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.31, while its 200-day Moving Average is $31.20. However, in the short run, LENZ Therapeutics Inc’s stock first resistance to watch stands at $23.39. Second resistance stands at $28.63. The third major resistance level sits at $32.48. If the price goes on to break the first support level at $14.30, it is likely to go to the next support level at $10.45. Assuming the price breaks the second support level, the third support level stands at $5.21.
LENZ Therapeutics Inc (NASDAQ: LENZ) Key Stats
There are currently 31,290K shares outstanding in the company with a market cap of 567.60 million. Presently, the company’s annual sales total 0 K according to its annual income of -49,770 K. Last quarter, the company’s sales amounted to 12,500 K and its income totaled -16,700 K.
